{"slideshow_credits": null, "snippet": "AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments.", "abstract": "AbbVie announces deal to buy Pharmacyclics for about $21 billion; Pharmacyclics makes cancer drug that may become one of best-selling treatments for the disease.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"lastname": "de la MERCED", "rank": 1, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "J."}, {"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 2, "organization": ""}], "original": "By MICHAEL J. de la MERCED and ANDREW POLLACK", "contributor": "David Gelles contributed reporting."}, "web_url": "http://www.nytimes.com/2015/03/05/business/dealbook/abbvie-to-pay-21-billion-for-pharmacyclics-maker-of-a-best-selling-cancer-treatment.html", "lead_paragraph": "AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments.", "headline": {"main": "AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Promising Cancer Drug", "print_headline": "AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Best-Selling Cancer Treatment"}, "_id": "54f7da3738f0d8579fff6174", "word_count": "725", "multimedia": [{"height": 126, "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg", "legacy": {"xlarge": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-03-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Pharmacyclics, Incorporated", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "AbbVie Inc", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Cancer", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Johnson & Johnson", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}